[Congressional Record Volume 167, Number 115 (Thursday, July 1, 2021)]
[House]
[Pages H3597-H3598]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]




                     EXECUTIVE COMMUNICATIONS, ETC.

   Under clause 2 of rule XIV, executive communications were taken from 
the Speaker's table and referred as follows:

       EC-1525. A letter from the Senior Congressional Liaison, 
     Bureau of Consumer Financial Protection, transmitting the 
     Bureau's Major final rule -- Protections for Borrowers 
     Affected by the COVID-19 Emergency Under the Real Estate 
     Settlement Procedures Act (RESPA), Regulation X [Docket No.: 
     CFPB-2021-0006] (RIN: 3170-AB07) received June 28, 2021, 
     pursuant to 5 U.S.C. 801(a)(1)(A); Public Law 104-121, Sec. 
     251; (110 Stat. 868); to the Committee on Financial Services.
       EC-1526. A letter from the Section Chief, Diversion Control 
     Division, Drug Enforcement Administration, Department of 
     Justice, transmitting the Department's final rule -- 
     Schedules of Controlled Substances: Placement of Remimazolam 
     in Schedule IV [Docket No.: DEA-658] received June 23, 2021, 
     pursuant to 5 U.S.C. 801(a)(1)(A); Public Law 104-121, Sec. 
     251; (110 Stat. 868); to the Committee on Energy and 
     Commerce.
       EC-1527. A letter from the Section Chief, Diversion Control 
     Division, Drug Enforcement Administration, Department of 
     Justice, transmitting the Department's final rule -- 
     Schedules of Controlled Substances: Removal of Samidorphan 
     From Control [Docket No.: DEA-665] received June 23, 2021, 
     pursuant to 5 U.S.C. 801(a)(1)(A); Public Law 104-121, Sec. 
     251; (110 Stat. 868); to the Committee on Energy and 
     Commerce.
       EC-1528. A letter from the Director, Office of 
     Congressional Affairs, Nuclear Regulatory Commission, 
     transmitting the Commission's final rule -- Guidance for 
     implementation of 10 CFR 50.69, ``Changes, Tests, and 
     Experiments'' [Regulatory Guide 1.187, Revision 3] received 
     June 25, 2021, pursuant to 5 U.S.C. 801(a)(1)(A); Public Law 
     104-121, Sec. 251; (110 Stat. 868); to the Committee on 
     Energy and Commerce.
       EC-1529. A letter from the Director, Office of 
     Congressional Affairs, Nuclear Regulatory Commission, 
     transmitting the Commission's issuance of regulatory guide -- 
     Implementation of Quality Assurance Criteria and 10 CFR 50.59 
     for Nuclear Power Plant Components Produced Using Advanced 
     Manufacturing Technologies [AMT Action Plan, Revision, 
     Subtask 2A] received June 25, 2021, pursuant to 5 U.S.C. 
     801(a)(1)(A); Public Law 104-121, Sec. 251; (110 Stat. 868); 
     to the Committee on Energy and Commerce.
       EC-1530. A letter from the Acting Director, Office of 
     Personnel Management, transmitting the Office's final rule -- 
     Promotion and Internal Placement (RIN: 3206-AN77) received 
     June 23, 2021, pursuant to 5 U.S.C. 801(a)(1)(A); Public Law 
     104-121, Sec. 251; (110 Stat. 868); to the Committee on 
     Oversight and Reform.
       EC-1531. A letter from the Associate Administrator for 
     Policy, Federal Motor Carrier Safety Administration, 
     Department of Transportation, transmitting the Department's 
     final rule -- Extension of Compliance Dates for Medical 
     Examiner's Certification Integration [Docket No.: FMCSA-2018-
     0152] (RIN: 2126-AC18) received June 28, 2021, pursuant to 5 
     U.S.C. 801(a)(1)(A); Public Law 104-121, Sec. 251; (110 Stat. 
     868); to the Committee on Transportation and Infrastructure.
       EC-1532. A letter from the Section Chief, Diversion Control 
     Division, Drug Enforcement Administration, Department of 
     Justice, transmitting the Department's final rule -- 
     Schedules of Controlled Substances:

[[Page H3598]]

     Placement of NM2201, 5F-AB-PINACA, 4-CN-CUMYL-BUTINACA, MMB-
     CHMICA, and 5F-CUMYL-P7AICA in Schedule I [Docket No.: DEA-
     479] received June 23, 2021, pursuant to 5 U.S.C. 
     801(a)(1)(A); Public Law 104-121, Sec. 251; (110 Stat. 868); 
     to the Committee on Energy and Commerce.

                          ____________________